BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-05-25 07:00 |
BERGENBIO TO PRESENT AT ABGSC SEMINAR
|
English | 5.1 KB | ||
| 2021-05-20 05:00 |
BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRI…
|
English | 192.4 KB | ||
| 2021-05-20 05:00 |
BERGENBIO TO PRESENT DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRI…
|
English | 6.0 KB | ||
| 2021-05-19 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
|
English | 241.4 KB | ||
| 2021-05-19 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
|
English | 8.8 MB | ||
| 2021-05-19 05:00 |
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2021
|
English | 7.6 KB | ||
| 2021-05-18 12:42 |
BERGENBIO PRESENTING AT SACHS 7[th] ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM
|
English | 199.1 KB | ||
| 2021-05-18 12:42 |
BERGENBIO PRESENTING AT SACHS 7[th] ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM
|
English | 5.2 KB | ||
| 2021-05-18 05:00 |
BERGENBIO KUNNGJØR TOPPLINJEDATA FRA FASE-II UTPRØVINGSSTUDIE AV BEMCENTINIB I …
|
Norwegian | 247.4 KB | ||
| 2021-05-18 05:00 |
BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN …
|
English | 250.8 KB | ||
| 2021-05-18 05:00 |
BERGENBIO KUNNGJØR TOPPLINJEDATA FRA FASE-II UTPRØVINGSSTUDIE AV BEMCENTINIB I …
|
Norwegian | 13.2 KB | ||
| 2021-05-18 05:00 |
BERGENBIO ANNOUNCES TOP LINE DATA FROM PHASE II TRIAL ASSESSING BEMCENTINIB IN …
|
English | 12.8 KB | ||
| 2021-05-12 14:03 |
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT EUROPEAN HEMATOLOGY ASSOCIATION (…
|
English | 185.1 KB | ||
| 2021-05-12 14:03 |
BERGENBIO TO PRESENT UPDATED CLINICAL DATA AT EUROPEAN HEMATOLOGY ASSOCIATION (…
|
English | 7.0 KB | ||
| 2021-05-11 05:00 |
BEMCENTINIB PRE-CLINICAL COVID-19 DATA PRESENTED AT VIRTUAL IMMUNOLOGY 2021
|
English | 206.0 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
